Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN

INCLUSION CRITERIA * Pathologically-proven ovarian cancer, or cancer of mullerian origin, that was or will be treated with a 1st-line taxane plus a platinum-based chemotherapy regimen. * GROUP A (painful neuropathy group): Subjective symptoms of painful peripheral neuropathy (burning, stabbing, throbbing, painful tingling, aching in the fingers and/or toes) that is greater than or equal to 10 on a scale of 0 to 100 in the neuropathic pain questionnaire * GROUP B (painless neuropathy group): Subjective symptoms of painless neuropathy (loss of sensation, worsening balance, strange sensation in fingers and/or toes) or no complaints related to neuropathy. * Life expectancy of 6 months * Ability to understand the study protocol, participate in testing, and the willingness to sign a written informed consent document. EXCLUSION CRITERIA * Received prior chemotherapy for ovarian cancer or cancer of mullerian origin other than 1st-line treatment with a taxane + platinum based regimen. * No concurrent investigational drugs. * Received investigational drugs suspected to cause peripheral neuropathy. * History of B12 deficiency * History of neuropathy or numbness/tingling suspicious for neuropathy, prior to the first dose of chemotherapy for ovarian cancer * Prior treatment for other cancers that included drugs known to cause neuropathy (including but are not limited to vinca-alkaloids, platinums, taxanes, bortizomib). * Known peripheral vascular disease * Chronic daily headache or hea…